The immune checkpoint blockade (ICB) targeting on PD-1/PD-L1 has shown remarkable
promise in treating cancers. However, the low response rate and frequently observed severe …

Simple Summary Immunotherapy against PD-1/PD-L1 dramatically improved outcomes in
non-small cell lung cancer patients. These treatments are more effective the higher the …

# 1 NEW YORK TIMES BESTSELLER• OVER ONE MILLION COPIES SOLD• A
groundbreaking manifesto on living better and longer that challenges the conventional …

Simple Summary Persistent activation of STAT3 is frequently observed in non-small cell lung
cancer and is associated with a poor prognosis. Given the multifaceted role of STAT3 …

Background Circulating soluble programmed death ligand 1 (sPD-L1) can negatively
regulate T-cell function and serve as a prognostic or predictive marker in a variety of …

Introduction In recent years, immunotherapy has become a pillar in the treatment of
advanced, non-oncogene-addicted non-small cell lung cancer (NSCLC). Programmed …

Background Monoclonal antibodies (ICI) targeting the immune checkpoint PD-1/PD-L1
alone or in combination with chemotherapy have demonstrated relevant benefits and …

Objectives: Immune checkpoint (ICP) expression in tumor cells could directly or indirectly
affect the results of immunotherapy. ICP ligands on tumor cells usually bind their immune …

Cancer immunotherapy, such as cancer vaccines and checkpoint blockades, has emerged
as a promising cancer therapy in battling cancer, and revolutionized the field of cancer …

Cytokine-induced killer (CIK) cells are heterogeneous cells composed mainly of CD3+
CD56+ T cells. As an important treatment method of adoptive therapy, it has shown …